Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM), ketanserin, and (R)-(+)-{alpha}-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-pipidinemethanol (MDL100907) in rats.
Very little is known about constitutive activity in vivo. This study examined whether constitutive activity and inverse agonism contribute to discriminative stimulus effects of drugs acting at serotonin (5-HT)(2A) receptors. Rats were trained to discriminate between saline and either 0.56 mg/kg 5-HT(2) receptor agonist 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM), 1.0 mg/kg 5-HT(2A) receptor antagonist ketanserin, or 0.1 mg/kg purported 5-HT(2A) receptor inverse agonist (R)-(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-pipidinemethanol (MDL100907). Discriminative control was established with each drug after 33 to 35 sessions. MDL100907 and ketanserin did not occasion DOM lever responding but attenuated the discriminative stimulus effects of DOM. DOM did not occasion responding on the drug-associated lever in rats discriminating MDL100907 or ketanserin, but attenuated the discriminative stimulus effects of both drugs. Ketanserin and ritanserin occasioned MDL100907-lever responding, whereas rats discriminating ketanserin responded only partially on the drug-associated lever after receiving MDL100907, ritanserin, or the alpha(1)-adrenergic antagonist prazosin. Combining prazosin with MDL100907 or ritanserin resulted in near-complete ketanserin-lever responding, indicating that the ketanserin stimulus involves both 5-HT(2A) and alpha(1)-adrenergic receptors. Administration of p-chlorophenylalanine methyl ester, then fenfluramine, significantly decreased cortical 5-HT, enhanced sensitivity to the discriminative stimulus effects of DOM, and occasioned partial MDL100907-lever responding. Collectively, these results show that DOM and MDL100907 discriminative stimulus effects are mediated by 5-HT(2A) receptors and that ketanserin discriminative stimulus effects involve both 5-HT(2A) and alpha(1)-adrenergic receptors. Results in 5-HT-depleted rats further suggest that the discriminative stimulus effects of MDL100907 might involve antagonism of endogenous 5-HT and/or inverse agonism at 5-HT(2A) receptors.
Li
Jun-Xu
JX
Department of Pharmacology, University of Texas Health Science Center at San Antonio, TX 78229, USA.
Unzeitig
Alison
A
Javors
Martin A
MA
Rice
Kenner C
KC
Koek
Wouter
W
France
Charles P
CP
D004290:DOM 2,5-Dimethoxy-4-Methylamphetamine / Q000494:pharmacology*; D000701:Analgesics, Opioid / Q000494:pharmacology; D000778:Anesthetics, Dissociative / Q000494:pharmacology; D000818:Animals; D003216:Conditioning, Operant / Q000187:drug effects; D004192:Discrimination, Psychological / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005464:Fluorobenzenes / Q000494:pharmacology*; D007649:Ketamine / Q000494:pharmacology; D007650:Ketanserin / Q000494:pharmacology*; D008297:Male; D009020:Morphine / Q000494:pharmacology; D010622:Phencyclidine / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D044402:Receptor, Serotonin, 5-HT2A / Q000187:drug effects; D018340:Receptors, Adrenergic, alpha-1 / Q000187:drug effects; D016713:Ritanserin / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000494:pharmacology*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*
D000701:Analgesics, Opioid; D000778:Anesthetics, Dissociative; D018691:Excitatory Amino Acid Antagonists; D005464:Fluorobenzenes; D010880:Piperidines; D044402:Receptor, Serotonin, 5-HT2A; D018340:Receptors, Adrenergic, alpha-1; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D016713:Ritanserin; D004290:DOM 2,5-Dimethoxy-4-Methylamphetamine; D007649:Ketamine; D009020:Morphine; D007650:Ketanserin; C079049:volinanserin; D010622:Phencyclidine
Gen Pharmacol. 2000 Aug;35(2):95-105
11707316
Eur J Pharmacol. 1983 Jul 22;91(2-3):189-96
6617740
Psychopharmacology (Berl). 1980;68(3):209-15
6771804
Pharmacol Biochem Behav. 1980 Oct;13(4):569-74
6449014
Neuropsychopharmacology. 2002 Apr;26(4):552-6
11927180
Curr Opin Pharmacol. 2007 Apr;7(2):146-50
17284360
Psychopharmacology (Berl). 1995 Oct;121(3):364-72
8584619
Neuropharmacology. 2005 Dec;49(8):1210-9
16165167
Behav Pharmacol. 2007 Jul;18(4):283-8
17551320
Pharmacol Rev. 1996 Sep;48(3):413-63
8888308
Mol Pharmacol. 1999 May;55(5):863-72
10220565
Br J Pharmacol. 2000 Feb;129(4):820-1
10683207
Bioorg Med Chem. 2000 Oct;8(10):2427-32
11058037
Biochem Pharmacol. 2006 Jun 14;71(12):1663-70
16460689
Neuropharmacology. 1993 Dec;32(12):1427-32
8152532
J Pharmacol Exp Ther. 2008 Feb;324(2):827-33
17993605
Proc Natl Acad Sci U S A. 1989 Oct;86(19):7321-5
2552439
Psychopharmacology (Berl). 1998 May;137(2):157-63
9630002
J Biol Chem. 1994 Apr 22;269(16):11687-90
7909313
Pharmacol Biochem Behav. 1982 Apr;16(4):553-6
7071088
Neuropsychopharmacology. 2002 Mar;26(3):340-7
11850148
J Biol Chem. 1999 Apr 2;274(14):9472-8
10092629
Neuropharmacology. 2003 Apr;44(5):604-15
12668046
J Pharmacol Exp Ther. 1995 Nov;275(2):1050-7
7473132
Arch Int Pharmacodyn Ther. 1954 Sep 1;99(1):32-49
13229418
Pharmacol Biochem Behav. 2000 Sep;67(1):103-10
11113489
Eur J Pharmacol. 1994 Oct 13;264(1):99-102
7530204
Learn Mem. 2003 Sep-Oct;10(5):355-62
14557608
Trends Pharmacol Sci. 2006 Feb;27(2):92-6
16406086
J Pharmacol Exp Ther. 2004 Sep;310(3):865-70
15113845
Pharmacol Biochem Behav. 2002 May;72(1-2):77-85
11900772
Pharmacol Ther. 2009 Feb;121(2):160-73
19109993
J Pharmacol Exp Ther. 2001 Oct;299(1):268-76
11561089
Psychopharmacology (Berl). 2006 Jan;184(2):173-81
16369834
Pharmacol Biochem Behav. 1975 May-Jun;3(3):429-35
125425
Psychopharmacology (Berl). 1999 Jan;141(2):162-8
9952040
Behav Pharmacol. 1991 Jun;2(3):225-231
11224066